Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aminoserine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminoserine SCHEMBL853082 | 1.00 | — | — | |
| Aminoserine SCHEMBL5114875 | 1.00 | — | — | |
| Aminoserine SCHEMBL8506214 | 0.97 | — | — | |
| Aminoserine SCHEMBL8506211 | 0.97 | — | — | |
| Aminoserine SCHEMBL8333262 | 0.97 | — | — | |
| Aminoserine SCHEMBL277837 | 0.97 | — | — | |
| Aminoserine SCHEMBL277836 | 0.97 | — | — | |
| Aminoserine SCHEMBL15668067 | 0.91 | SLC1A1 (0.37) | — | |
| Aminoserine SCHEMBL3166789 | 0.86 | SLC1A1 (0.34) | — | |
| Aminoserine SCHEMBL17491742 | 0.86 | LMNA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533708-B | Preparation method of chiral N-tert-butoxycarbonylmorpholine-3-carboxylic acid | 上海馨远医药科技有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-111533708-A | Preparation method of chiral N-tert-butoxycarbonylmorpholine-3-carboxylic acid | 上海馨远医药科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| CN-105646252-A | Synthesis method of H-SER-NH2*HCL | 吉尔生化（上海）有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-1221527-C | Novel crystal of stilbene derivative and process for producing the same | AJINOMOTO KK (JP) | 2005-10-05 | — | — | CN | claimed |
| CN-1418186-A | Novel crystal of stilbene derivative and process for producing the same | AJINOMOTO KK (JP) | 2003-05-14 | — | — | CN | claimed |
| US-20250320189-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-10-16 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4532479-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | disclosed |
| US-5637712-A | CATALYTIC HYDROGENNATION | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5606062-A | STEREOSELECTIVE REDUCTION | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5399696-A | Excitatory amino acid receptor antagonists; nervous system disorders | ELI LILLY AND COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| CN-1091129-A | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1994-08-24 | — | — | CN | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| CN-1022837-C | Process for preparation of cephem derivatives and intermediates therefor | EISAI CO LTD (JP) | 1993-11-24 | — | — | CN | disclosed |
| CN-1036769-A | The method for preparing Cephem Derivative and intermediate thereof | EISAI CO LTD (JP) | 1989-11-01 | — | — | CN | disclosed |